Preliminary analysis of paclitaxel, carboplatin, and concurrent radiation in the treatment of patients with advanced non-small cell lung cancer

H. Choy, W. Akerley, H. Safran, S. Graziano, C. Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Previously untreated patients with stage IIIA or IIIB non-small cell lung cancer were entered into a phase II study to evaluate the activity and toxicity of combined peclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin with concurrent radiation. Patients received peclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2 weekly for 7 weeks, followed by radiation to the primary tumor and regional lymph nodes (44 Gy) and, later, by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve 6) every 3 weeks. From March 1995 to February 1996, 23 patients have entered the study. The overall response rate was 82% and the major toxicity was esophagitis. Nine patients (45%) experienced grade 3 or 4 esophagitis at the end of the concurrent phase; seven of the nine patients recovered within 2 weeks and received an additional two cycles of combined paclitaxel/carboplatin. Only one patient (4%) had grade 4 pneumonitis, and again, the patient recovered within 2 weeks and received posterior chemotherapy. With a high response rate and acceptable toxicity, therapy with peclitaxel, carboplatin, and radiation is a promising treatment for patients with locally advanced non-small cell lung cancer.

Original languageEnglish (US)
JournalSeminars in Radiation Oncology
Volume7
Issue number2 SUPPL. 1
StatePublished - 1997

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
lungs
cancer
Radiation
radiation
toxicity
Therapeutics
Esophagitis
grade
tumors
cycles
lymphatic system
curves
chemotherapy
acceleration (physics)
therapy
Neoplasms
Pneumonia

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Preliminary analysis of paclitaxel, carboplatin, and concurrent radiation in the treatment of patients with advanced non-small cell lung cancer. / Choy, H.; Akerley, W.; Safran, H.; Graziano, S.; Chung, C.

In: Seminars in Radiation Oncology, Vol. 7, No. 2 SUPPL. 1, 1997.

Research output: Contribution to journalArticle

@article{a354fda715fd4fa09660640cb5b6d52e,
title = "Preliminary analysis of paclitaxel, carboplatin, and concurrent radiation in the treatment of patients with advanced non-small cell lung cancer",
abstract = "Previously untreated patients with stage IIIA or IIIB non-small cell lung cancer were entered into a phase II study to evaluate the activity and toxicity of combined peclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin with concurrent radiation. Patients received peclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2 weekly for 7 weeks, followed by radiation to the primary tumor and regional lymph nodes (44 Gy) and, later, by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve 6) every 3 weeks. From March 1995 to February 1996, 23 patients have entered the study. The overall response rate was 82{\%} and the major toxicity was esophagitis. Nine patients (45{\%}) experienced grade 3 or 4 esophagitis at the end of the concurrent phase; seven of the nine patients recovered within 2 weeks and received an additional two cycles of combined paclitaxel/carboplatin. Only one patient (4{\%}) had grade 4 pneumonitis, and again, the patient recovered within 2 weeks and received posterior chemotherapy. With a high response rate and acceptable toxicity, therapy with peclitaxel, carboplatin, and radiation is a promising treatment for patients with locally advanced non-small cell lung cancer.",
author = "H. Choy and W. Akerley and H. Safran and S. Graziano and C. Chung",
year = "1997",
language = "English (US)",
volume = "7",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Preliminary analysis of paclitaxel, carboplatin, and concurrent radiation in the treatment of patients with advanced non-small cell lung cancer

AU - Choy, H.

AU - Akerley, W.

AU - Safran, H.

AU - Graziano, S.

AU - Chung, C.

PY - 1997

Y1 - 1997

N2 - Previously untreated patients with stage IIIA or IIIB non-small cell lung cancer were entered into a phase II study to evaluate the activity and toxicity of combined peclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin with concurrent radiation. Patients received peclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2 weekly for 7 weeks, followed by radiation to the primary tumor and regional lymph nodes (44 Gy) and, later, by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve 6) every 3 weeks. From March 1995 to February 1996, 23 patients have entered the study. The overall response rate was 82% and the major toxicity was esophagitis. Nine patients (45%) experienced grade 3 or 4 esophagitis at the end of the concurrent phase; seven of the nine patients recovered within 2 weeks and received an additional two cycles of combined paclitaxel/carboplatin. Only one patient (4%) had grade 4 pneumonitis, and again, the patient recovered within 2 weeks and received posterior chemotherapy. With a high response rate and acceptable toxicity, therapy with peclitaxel, carboplatin, and radiation is a promising treatment for patients with locally advanced non-small cell lung cancer.

AB - Previously untreated patients with stage IIIA or IIIB non-small cell lung cancer were entered into a phase II study to evaluate the activity and toxicity of combined peclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin with concurrent radiation. Patients received peclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2 weekly for 7 weeks, followed by radiation to the primary tumor and regional lymph nodes (44 Gy) and, later, by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve 6) every 3 weeks. From March 1995 to February 1996, 23 patients have entered the study. The overall response rate was 82% and the major toxicity was esophagitis. Nine patients (45%) experienced grade 3 or 4 esophagitis at the end of the concurrent phase; seven of the nine patients recovered within 2 weeks and received an additional two cycles of combined paclitaxel/carboplatin. Only one patient (4%) had grade 4 pneumonitis, and again, the patient recovered within 2 weeks and received posterior chemotherapy. With a high response rate and acceptable toxicity, therapy with peclitaxel, carboplatin, and radiation is a promising treatment for patients with locally advanced non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030915775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030915775&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030915775

VL - 7

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2 SUPPL. 1

ER -